Study Of 215 Patients Who Required High Flow Nasal Cannula During Corona Virus Epidemic

Background:High flow nasal cannula is a newer modality of treatment for hypoxemic respiratory failure. Present study is conducted to evaluate demographic characteristics, co-morbidities and outcome parameters of patients on High flow nasal cannula. Material And Methods:In retrospective observational study all patients on High flow nasal canula with covid-19 were evaluated for demographic characteristics and outcome with comorbidities during study period.Result:Maximum number of patients belongs to age group 51-60 years. Highest mortality was in the age group of 61-70 years.Conclusion:The High flow nasal cannula therapy may provide important newer modality and helpful in patients with respiratory failure.

Bronquiolitis aguda: tratamiento de la insuficiencia respiratoria / Acute bronchiolitis: treatment of respiratory insufficiency

The severe respiratory insufficiency (SRI) caused by acute bronchitis whose main etiology is the respiratory syncytial virus is the main cause of under 2-year-old children hospitalization during the winter months, especially in the risk groups. Its treatment is mainly based in general measures, administration of respiratory support with standard oxygen therapy, non-invasive ventilation, invasive mechanical ventilation or the emerging high flow nasal cannula therapy, which these past few years has become an easy alternative of use, well tolerated, secure to be used in emergency rooms, basic rooms and pediatric intensive care units. The election of therapy will depend of the patient severity, the level of complexity of the healthcare center and the experience in the different treatment modalities of the health team. It is essential to carry out protocols and guidelines for the management of SRI treatment caused by acute bronchitis for emergency services, basic rooms and pediatric intensive care.

La insuficiencia respiratoria aguda (IRA) causada por bronquiolitis aguda (BA), cuya principal etiología es el virus respiratorio sincicial (VRS), es la principal causa de hospitalizaciones en menores de 2 años durante los meses de invierno, especialmente en grupos de riesgo. Su manejo se basa principalmente en medidas generales, administración de soporte respiratorio con oxigenoterapia estándar, ventilación no invasiva (VNI), ventilación mecánica invasiva (VMI) o la emergente terapia con cánula nasal de alto flujo (CNAF), que se ha transformado en los últimos años en una alternativa de fácil uso, bien tolerada, segura para ser usada en los servicios de urgencia, salas básicas y unidades de cuidados intensivos pediátricos (UCIP). La elección de la terapia a utilizar dependerá de la gravedad del paciente, del nivel de complejidad del centro asistencial y de la experiencia en las distintas modalidades de tratamiento del equipo de salud. Es fundamental realizar protocolos y guías de manejo de tratamiento de la IRA causada por BA tanto para servicios de urgencia, salas básicas como cuidados intensivos pediátricos.

Efficacy and safety of humidified high flow nasal cannula in chronic obstructive pulmonary disease complicated with type 2 respiratory failure patients after extubation: A randomized controlled trial / 第二军医大学学报

Objective: To compare the efficacy and safety between humidified high flow nasal cannula (HHFNC) and noninvasive positive pressure ventilation (NPPV) in patients with chronic obstructive pulmonary disease (COPD) complicated with type 2 respiratory failure after extubation. Methods: Seventy-two patients with COPD complicated with type 2 respiratory failure were enrolled after extubation and were randomized into HHFNC group and NPPV group at 1: 1 ratio, with 36 patients in each group. The blood gas analysis index, respiratory rate, heart rate, mean arterial pressure, reintubation rate, incidence of tracheotomy, intensive care unit stay, incidence of adverse events and mortality were compared between the two groups before treatment and 2, 12, 24 h after treatment. Results: The pH at 24 h, partial pressure of oxygen in artery (PaO2) at 2 h and 12 h, and oxygenation index (PaO2/FiO2) at 2 h and 12 h after treatment were significantly higher in the HHFNC group compared with the NPPV group (all P0.05), while the overall incidence of adverse events, intolerance rate, flatulence rate and aspiration rate were significantly lower in the HHFNC group than those in the NPPV group (all P 0.05). Conclusion: The short-time efficacy and safety of HHFNC are better than NPPV in treatment of COPD complicated with type 2 respiratory failure.